Document Detail


Attenuation of corticotropin releasing factor-induced hypotension in anesthetized rats with the CRF antagonist, alpha-helical CRF9-41; comparison with effect on ACTH release.
MedLine Citation:
PMID:  1320258     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effect of pretreatment with the corticotropin releasing factor (CRF-41) antagonist, alpha-helical CRF(9-41), on the hypotensive response obtained on peripheral administration of CRF-41 has been assessed in anesthetized Wistar rats. A single IV bolus dose of rat CRF-41 (2 nmol, at 0 min) produced a hypotensive effect which was rapid in onset (-52 mmHg at +1 min) and sustained throughout the 60-min study period (-42, -40, -26 and -16 mmHg at +3, +10, +30 and +60 min, respectively). The antagonist [alpha CRF(9-41)] was administered in consecutive bolus doses of 12.5, 25 and 50 nmol at -15, -10 and -5 min, respectively. This had no effect on mean arterial blood pressure (MABP) or heart rate, nor did it change significantly the magnitude of the initial rapid fall in MABP when CRF-41 was administered (-45 mmHg at +1 min). However, following pretreatment with alpha CRF(9-41), MABP returned to control values within 3 min and the sustained period of hypotension was completely blocked. Administration of CRF-41 resulted in 44% and 142% increases in norepinephrine and epinephrine measured at +60 min. Pretreatment with the antagonist attenuated the rise in circulating catecholamine levels observed after CRF-41 administration. In comparison, pretreatment with the antagonist did not alter the ACTH response to CRF-41 at +1 and +3 min and only reduced ACTH levels by 28% (p less than 0.05), 43% (p less than 0.001) and 41% (p less than 0.01) at 10, 30 and 60 min, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
R Corder; D Turnill; N Ling; R C Gaillard
Related Documents :
1802988 - Changes in ingestive behavior induced by intracranial injection of spermine.
10579318 - Mechanisms by which blood levels of interleukin-6 (il-6) are elevated after intracerebr...
3550528 - Suppression by glucocorticoid of the immunoreactivity of corticotropin-releasing factor...
43498 - Effect of runway training on rat brain tyrosine hydroxylase: differential effect of con...
20493538 - Striatal volume changes in a rat model of childhood attention-deficit/hyperactivity dis...
6144538 - Reduction of hypothalamic norepinephrine does not alter the osmoregulation of vasopress...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Peptides     Volume:  13     ISSN:  0196-9781     ISO Abbreviation:  Peptides     Publication Date:    1992 Jan-Feb
Date Detail:
Created Date:  1992-08-06     Completed Date:  1992-08-06     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8008690     Medline TA:  Peptides     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1-6     Citation Subset:  IM    
Affiliation:
Department of Medicine, University Hospital, Geneva, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenocorticotropic Hormone / drug effects,  secretion*
Anesthesia, Intravenous
Animals
Blood Pressure Determination
Catecholamines / blood
Cells, Cultured
Corticotropin-Releasing Hormone / antagonists & inhibitors*,  pharmacology*
Female
Hypotension / metabolism*
Neuropeptide Y / blood
Peptide Fragments / pharmacology*
Pituitary Gland, Anterior / cytology,  metabolism
Protein Conformation
Rats
Chemical
Reg. No./Substance:
0/Catecholamines; 0/Neuropeptide Y; 0/Peptide Fragments; 9002-60-2/Adrenocorticotropic Hormone; 9015-71-8/Corticotropin-Releasing Hormone; 96118-75-1/corticotropin releasing hormone (9-41)

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Characterization of a retinoic acid responsive element isolated by whole genome PCR.
Next Document:  The MSH/ACTH analog ORG 2766 in anxiety disorders.